{"id":28610,"date":"2023-11-23T12:28:48","date_gmt":"2023-11-23T12:28:48","guid":{"rendered":"https:\/\/breastcancer.knowledgehub.wiley.com\/articoli\/copertura-esmo-2023-parte-1durata-25-min\/"},"modified":"2024-01-22T14:54:54","modified_gmt":"2024-01-22T14:54:54","slug":"copertura-esmo-2023-parte-1","status":"publish","type":"post","link":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/","title":{"rendered":"Copertura ESMO 2023 &#8211; Parte 1<br><small>Durata: 25 min<\/small>"},"content":{"rendered":"\n\n\t<p>Il Prof. Harbeck presenta una rapida panoramica dei dati a 5 anni dello studio monarchE- sul ruolo di abemaciclib adiuvante pi\u00f9 terapia endocrina nel tumore del seno in fase iniziale ad alto rischio, HR- positivo, HER2-negativo; i Key Opinion Leaders forniscono una valutazione critica dei dati e del futuro di questa terapia e discutono le relative presentazioni e le questioni cliniche aperte che devono essere affrontate.<\/p>\n  <style>\n  video-js.video-js.vjs-fluid:not(.vjs-audio-only-mode) {\n    padding-top: 56.25%;\n  }\n  <\/style><video-js\n    data-account=\"656326989001\"\n    data-player=\"MtqTTqu2Of\"\n    data-embed=\"default\"\n    controls=\"\"\n    data-video-id=\"6342586300112\"\n    data-playlist-id=\"\"\n    data-application-id=\"\"><\/video-js>\n\t<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/03\/Chapters-Icon.png\" alt=\"\" width=\"42\" height=\"30\" \/> Clicca sull&#8217;icona dei Capitoli nella barra degli strumenti del video per navigare tra le sezioni del video.<\/p>\n<p>Durata: 25 min<\/p>\n01.10 &#8211; Critica dei dati<br \/>\n06.42 &#8211; Sopravvivenza<br \/>\n08.42 &#8211; Biomarcatori<br \/>\n14.45 &#8211; Altri studi clinici<br \/>\n18.38 &#8211; Riduzione della dose, tossicit\u00e0 ed efficacia<br \/>\n21.25 &#8211; Espressione dei recettori nei pazienti, marcatori prognostici e predittivi<br \/>\n23:47 &#8211; Riassunto &#8211; Messaggi chiave\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fit%2F%3Fp%3D28610%26fl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tFacebook\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/twitter.com\/share?url=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fit%2F%3Fp%3D28610%26fl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tTwitter\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fit%2F%3Fp%3D28610%26fl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tLinkedin\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\n","protected":false},"excerpt":{"rendered":"<p>Risultati pi\u00f9 recenti sugli inibitori delle CDK4\/6 nei dati sul tumore del seno in fase iniziale positivo al recettore ormonale, HER2-negativo.<\/p>\n","protected":false},"author":10,"featured_media":28540,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[121],"tags":[181],"class_list":["post-28610","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-commenti-dei-key-opinion-leader","tag-esmo-2023-it"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Copertura ESMO 2023 - Parte 1Durata: 25 min - Risorse sul Tumore del seno per i professionisti della Salute<\/title>\n<meta name=\"description\" content=\"Il Prof. Harbeck e il Prof. Barrios discutono i risultati pi\u00f9 recenti sugli inibitori delle CDK4\/6 nel tumore del seno in fase iniziale positivo al recettore ormonale, HER2-negativo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Copertura ESMO 2023 - Parte 1Durata: 25 min - Risorse sul Tumore del seno per i professionisti della Salute\" \/>\n<meta property=\"og:description\" content=\"Il Prof. Harbeck e il Prof. Barrios discutono i risultati pi\u00f9 recenti sugli inibitori delle CDK4\/6 nel tumore del seno in fase iniziale positivo al recettore ormonale, HER2-negativo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Risorse sul Tumore del seno per i professionisti della Salute\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-23T12:28:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-22T14:54:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"281\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mike Echalaz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mike Echalaz\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/\"},\"author\":{\"name\":\"Mike Echalaz\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c\"},\"headline\":\"Copertura ESMO 2023 &#8211; Parte 1 Durata: 25 min\",\"datePublished\":\"2023-11-23T12:28:48+00:00\",\"dateModified\":\"2024-01-22T14:54:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/\"},\"wordCount\":129,\"publisher\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization\"},\"image\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg\",\"keywords\":[\"ESMO 2023\"],\"articleSection\":[\"Comment dei Key Opinion Leader\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/\",\"name\":\"Copertura ESMO 2023 - Parte 1 Durata: 25 min - Risorse sul Tumore del seno per i professionisti della Salute\",\"isPartOf\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg\",\"datePublished\":\"2023-11-23T12:28:48+00:00\",\"dateModified\":\"2024-01-22T14:54:54+00:00\",\"description\":\"Il Prof. Harbeck e il Prof. Barrios discutono i risultati pi\u00f9 recenti sugli inibitori delle CDK4\/6 nel tumore del seno in fase iniziale positivo al recettore ormonale, HER2-negativo.\",\"breadcrumb\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg\",\"contentUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg\",\"width\":500,\"height\":281},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Copertura ESMO 2023 &#8211; Parte 1Durata: 25 min\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/\",\"name\":\"Risorse sul Tumore del seno per i professionisti della Salute\",\"description\":\"Breast Cancer focused knowledge hub of resources, webinars, latest research and clinical updates for health care professionals who are treating patients living with Breast Cancer\",\"publisher\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization\",\"name\":\"Wiley\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg\",\"contentUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg\",\"width\":696,\"height\":696,\"caption\":\"Wiley\"},\"image\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c\",\"name\":\"Mike Echalaz\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Copertura ESMO 2023 - Parte 1Durata: 25 min - Risorse sul Tumore del seno per i professionisti della Salute","description":"Il Prof. Harbeck e il Prof. Barrios discutono i risultati pi\u00f9 recenti sugli inibitori delle CDK4\/6 nel tumore del seno in fase iniziale positivo al recettore ormonale, HER2-negativo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/","og_locale":"it_IT","og_type":"article","og_title":"Copertura ESMO 2023 - Parte 1Durata: 25 min - Risorse sul Tumore del seno per i professionisti della Salute","og_description":"Il Prof. Harbeck e il Prof. Barrios discutono i risultati pi\u00f9 recenti sugli inibitori delle CDK4\/6 nel tumore del seno in fase iniziale positivo al recettore ormonale, HER2-negativo.","og_url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/","og_site_name":"Risorse sul Tumore del seno per i professionisti della Salute","article_published_time":"2023-11-23T12:28:48+00:00","article_modified_time":"2024-01-22T14:54:54+00:00","og_image":[{"width":500,"height":281,"url":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg","type":"image\/jpeg"}],"author":"Mike Echalaz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mike Echalaz"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#article","isPartOf":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/"},"author":{"name":"Mike Echalaz","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c"},"headline":"Copertura ESMO 2023 &#8211; Parte 1 Durata: 25 min","datePublished":"2023-11-23T12:28:48+00:00","dateModified":"2024-01-22T14:54:54+00:00","mainEntityOfPage":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/"},"wordCount":129,"publisher":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization"},"image":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage"},"thumbnailUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg","keywords":["ESMO 2023"],"articleSection":["Comment dei Key Opinion Leader"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/","name":"Copertura ESMO 2023 - Parte 1 Durata: 25 min - Risorse sul Tumore del seno per i professionisti della Salute","isPartOf":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage"},"image":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage"},"thumbnailUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg","datePublished":"2023-11-23T12:28:48+00:00","dateModified":"2024-01-22T14:54:54+00:00","description":"Il Prof. Harbeck e il Prof. Barrios discutono i risultati pi\u00f9 recenti sugli inibitori delle CDK4\/6 nel tumore del seno in fase iniziale positivo al recettore ormonale, HER2-negativo.","breadcrumb":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#primaryimage","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg","contentUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/11\/ESMO-Part-1-FI.jpg","width":500,"height":281},{"@type":"BreadcrumbList","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/copertura-esmo-2023-parte-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/"},{"@type":"ListItem","position":2,"name":"Copertura ESMO 2023 &#8211; Parte 1Durata: 25 min"}]},{"@type":"WebSite","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/","name":"Risorse sul Tumore del seno per i professionisti della Salute","description":"Breast Cancer focused knowledge hub of resources, webinars, latest research and clinical updates for health care professionals who are treating patients living with Breast Cancer","publisher":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization","name":"Wiley","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg","contentUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg","width":696,"height":696,"caption":"Wiley"},"image":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c","name":"Mike Echalaz"}]}},"_links":{"self":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts\/28610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/comments?post=28610"}],"version-history":[{"count":9,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts\/28610\/revisions"}],"predecessor-version":[{"id":29011,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts\/28610\/revisions\/29011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/media\/28540"}],"wp:attachment":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/media?parent=28610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/categories?post=28610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/tags?post=28610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}